Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics — Merger or Acquisition (December 2021)
15 slides from Ortho Clinical Diagnostics's merger presentation, Dec 23, 2021
Slide 1: Quidel Corporation's Acquisition of Ortho Clinical Diagnostics Investor Conference Call
Quidel Corporation’s Acquisition of Ortho Clinical Diagnostics Investor Conference Call December 23, 2021 Copyright © 2021 Quidel Corporation. All rights reserved.
Slide 2: Forward-Looking Statements and Additional Information
Forward-Looking Statements and Additional Information NO OFFER OR SOLICITATION The information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote or
Slide 3: Compelling Strategic Rationale and Value Creation Opportunity
Compelling Strategic Rationale and Value Creation Opportunity • Innovative solutions spanning the diagnostics continuum – high- $50B volume to rapid point-of-care and home use Definitive Combined Market • Multiple modalities to address increasingly diverse clinical and Leadership Opportunity custome
Slide 4: Transaction Overview
Transaction Overview • Quidel to acquire Ortho for $24.68 per share of common stock, funded through a combination of cash and newly issued shares in the combined company • Total equity value of ~$6.0 billion Transaction • Ortho shareholders will receive $7.14 per common share and 0.1055 shares of co
Slide 5: Ortho Clinical Diagnostics Business Overview
Ortho Clinical Diagnostics Business Overview (2) Leading In Vitro Diagnostics Pure-play Revenue by Business Segment ($ in millions) • Rich 80+ year history of leadership in mid- and high-volume Non-Core 2% testing • A global leader in screening and diagnosis across clinical chemistry, immunoassay an
Slide 6: Enhances Quidel's Ability to Address Key Market Trends
Enhances Quidel’s Ability to Address Key Market Trends Trends Implications Rising demand of diagnostic Decentralization of care testing: 1 and testing • Manage chronic conditions • New diagnostic tests to support recently discoveredmarkers Emergence of new • Repeated therapy monitoring Positioned to
Slide 7: Leadership Across Large and Growing Market Opportunities
Leadership Across Large and Growing Market Opportunities Total Addressable Market: $50 Billion Point-of-care Clinical Laboratories Transfusion Medicine Market Leader in Respiratory Market Leader in acute care and Global Leader in “STAT” Labs Immunohematology Rapid Testing ORTHO VISION® Sofia® Savann
Slide 8: Multiple Drivers for Clear Ongoing Value Creation
Multiple Drivers for Clear Ongoing Value Creation Stronger financial profile Enhanced R&D • Durable business model • Significant cost Commercial and revenue • Capabilities of leverage synergies both • Greater financial Broad organizations flexibility for portfolio • Menu expansion • Global footprint
Slide 9: Capabilities Spanning Key Setting and Critical Indications
Capabilities Spanning Key Setting and Critical Indications Clinical Setting Disease Indication Decentralized Settings • Infectious Disease • Cardiac At-Home / At-Home / Over The Therapeutic “PhAST” • Sepsis Counter Monitoring • Clinical Chemistry Clinics • Special Chemistry Freestanding Emergency Ph
Slide 10: Global Footprint Provides Channel to Accelerate Compelling Product Portfolio
Global Footprint Provides Channel to Accelerate Compelling Product Portfolio Galway, Ireland Prague, Czech Republic Pencoed, Wales Rochester, NY Strasbourg, France Kornwestheim, Germany Beverly, MA Athens, OH San Diego, CA Tokyo, Japan Waltham, MA Shanghai, China Quidel / Ortho Sales Presence Mexico
Slide 11: Complementary Offerings to Reference Labs, Hospitals, Clinics, & At-Home Testing
Complementary Offerings to Reference Labs, Hospitals, Clinics, & At-Home Testing Research Reference Labs Hospitals Clinics Home • OTC and Self-Testing • Pharma CRO Univ. • LabCorp, Quest, ARUP, etc. • Large Hospitals Lab • Free-Standing ER • Public Health Clinic • Public Health • Small Hospitals Lab
Slide 12: Further Diversifies Quidel's Footprint and Revenue Streams
Further Diversifies Quidel’s Footprint and Revenue Streams Quidel Pro Forma $1.9B $2.0B $3.9B TTM Q3’21 Revenue TTM Q3’21 Revenue TTM Q3’21 Revenue RoW China 5% 3% Other EMEA Other 13% 4% 21% China Revenue 8% North EMEA by China America 9% 13% 53% North Geography North America America EMEA 70% 88% 1
Slide 13: Addition of Ortho Creates a Leading Top-7 IVD Pure-Play
Addition of Ortho Creates a Leading Top-7 IVD Pure-Play FY 2020 Revenue ($ in millions) (1) $15,431 (1) $10,805 Top-7 (1) $7,403 Diagnostics Player (2) $5,343 (1) $4,989 $3,809 100,000+ $3,428 Quidel Pro Forma Instrument Installed Base $2,728 (1) Across All Platforms $2,500 (1) $2,068 $1,766 130+ $1
Slide 14: Compelling Strategic Rationale and Value Creation Opportunity
Compelling Strategic Rationale and Value Creation Opportunity • Innovative solutions spanning the diagnostics continuum – high- $50B volume to rapid point-of-care and home use Definitive Combined Market • Multiple modalities to address increasingly diverse clinical and Leadership Opportunity custome
Slide 15: QUIDEL
cs QUIDEL
Ortho Clinical Diagnostics Holdings — Merger or Acquisition (December 2021) on 6ix